Our proprietary antibody technologies for target identification and antibody generation enable us to isolate specific human monoclonal antibodies that can recognize and bind to virtually any antigen of interest.
We use this platform to generate a stream of differentiated product candidates across a variety of angiogenesis-related indications in the areas of oncology and chronic inflammation.
In addition, we develop and manufacture human monoclonal antibodies for selected pharmaceutical companies.
At our headquarters in Siena, we operate an in-house GMP manufacturing unit, which enables us to conduct GMP manufacturing and CRO drug development activities in an integrated manner.
Weber et al. (2014) PLoS One, 9, e100000
Cyranka-Czaja et al. (2012) Biochem Biophys Res Commun, 419, 250-5
Villa et al. (2011) MAbs, 3, 264-72
Sommavilla et al. (2010) J Immunol Methods, 353, 41-3
Villa et al. (2008) Int J Cancer, 122, 2405-13
Rybak et al. (2007) Cancer Res, 67, 10948-57
Silacci et al. (2005) Proteomics, 5, 2340-50
Giovannoni et al. (2001) Nucleic Acids Res, 29, E27
Viti et al. (2000) Methods Enzymol, 326, 480-505
Pini et al. (1998) J Biol Chem, 273, 21769-76